Oscar Health Inc
NYSE:OSCR

Watchlist Manager
Oscar Health Inc Logo
Oscar Health Inc
NYSE:OSCR
Watchlist
Price: 29.16 USD -2.57% Market Closed
Market Cap: $8.8B

Wall St Price Targets

OSCR Price Targets Summary
Oscar Health Inc

Wall Street analysts forecast OSCR stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OSCR is 21.42 USD with a low forecast of 8.08 USD and a high forecast of 31.5 USD.

Lowest Forecast
Price Target
8.08 USD
72% Downside
Average Forecast
Price Target
21.42 USD
27% Downside
Highest Forecast
Price Target
31.5 USD
8% Upside
Oscar Health Inc Competitors:
Price Targets
SOC
Flame Acquisition Corp
247% Upside
PRI
Primerica Inc
10% Upside
KINS
Kingstone Companies Inc
25% Upside
MAIN
Main Street Capital Corp
19% Upside

Revenue
Forecast

91% / Year
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
91% / Year
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Over the last 5 years, the compound annual growth rate for Revenue has been 91%. The projected CAGR for the next 3 years is 25%.

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is OSCR's stock price target?
Price Target
21.42 USD

According to Wall Street analysts, the average 1-year price target for OSCR is 21.42 USD with a low forecast of 8.08 USD and a high forecast of 31.5 USD.

What is the Revenue forecast for Oscar Health Inc?
Projected CAGR
25%

Over the last 5 years, the compound annual growth rate for Revenue has been 91%. The projected CAGR for the next 3 years is 25%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett